CClinicalTrials.gg
Status unknownNCT00857363CTTUpdated Jan 15, 2010

Colonic Transit Time Validation Study

An observational study in Constipation, sponsored by The SmartPill Corporation. Status unknown at 13 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2010-01-15.

Sponsored by The SmartPill Corporation · Observational

The sponsor has not verified this record recently (last verified Jan 2010), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
210
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The protocol described herein is designed to provide clinical evidence of the substantial equivalence of SmartPill GI Monitoring System (SP) to the Sitzmarks (Konsyl Pharmaceuticals, Easton, MD) radio-opaque markers (ROM). The trial will enroll symptomatic subjects who meet Rome III criteria (1) for chronic functional constipation.

Read the detailed description

The primary aim of this study is to assess the equivalence of SP to ROM through characterization of device agreement using SP cutoffs for colonic and whole gut transit (59hrs and 73 hrs respectively) derived from the above mentioned study. The cutoffs are derived from the 95th percentile of the healthy subjects in the study. Demonstration of agreement will also serve to validate these SP cutoffs. Device agreement will be evaluated by comparing the percentage of subjects identified with slow transit versus normal transit with SmartPill to the percentage of subjects identified with slow versus normal transit with ROM in the study population. The colonic transit time results will serve as the primary measure for slow versus normal transit for SmartPill. For ROM test we will employ the Metcalf protocol which provides a measure of whole gut transit to compare the SmartPill results to. Additionally, we will characterize gastric emptying and small bowel transit time of the SmartPill in this population. The SmartPill test will be administered simultaneously with ROM. A modified Metcalf procedure will be employed for characterization of slow transit by ROM.

The SmartPill GI Monitoring System offers an alternative non-invasive method for characterizing disorders of the stomach. The system consists of an ingestible capsule that houses sensors for pH, temperature, and pressure, a receiver for receiving and storing signals from the capsule, and software for displaying data on a personal computer. The capsule samples at regular intervals and transmits the sensed pH, pressure, and temperature data to a portable receiver worn by the subject. After test completion, the recorded data is downloaded to a personal computer for subsequent evaluation. This trial is for subjects 18 years of age to 80 years of age.

02

Conditions studied

  • Constipation

Browse trials for

Keywords

  • capsule
  • constipation
  • whole gut transit
  • colonic transit
  • gastric emptying
  • small bowel transit
03

In context

Constipation

1,018 studies on the registry are indexed under Constipation; 139 are open to participants now.

This study's planned enrollment of 210 is above the median of 100 across 129 observational studies indexed under Constipation.

Browse Constipation studies →

Lead sponsor

The SmartPill Corporation is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with constipation referred to a tertiary motility center

Inclusion criteria

  1. Males and females between ages of 18-80 years of age with symptoms of chronic functional constipation for at least one year.
  2. Self reported bowel movement frequency of \< 2 bowel movements/week for at least 3 of the last 6 months.
  3. Presenting at least one of the following symptoms as defined by Rome III criteria

    • Feeling of incomplete evacuation with > 25% of bowel movements
    • Digital maneuvers with > 25% of bowel movements
    • Hard stools with > 25% of bowel movements
    • Feeling of blockage with > 25% of bowel movements
    • Straining with > 25% of bowel movements
  4. Constipation, not abdominal pain, as the predominant symptom.
  5. Ability to stop laxatives, prokinetic agents, and narcotic analgesic agents 3 days prior to SP and ROM ingestion visit and during the study period.
  6. Ability to stop proton pump inhibitors for seven days and Histamine2 blockers for three days prior to and the day of SmartPill ingestion.
  7. No evidence of metabolic disease (hypothyroidism, uncontrolled diabetes, electrolyte imbalance).
  8. A normal colonoscopy or barium enema within 5 years for individuals over 50 years of age.

Exclusion criteria

-

Exclusion Criteria:

  1. Participation in the previous SmartPill Whole gut transit Study titled "Assessment of Whole Gut Transit Time Using the SmartPill Capsule: A Multicenter Study" Protocol Number 122205
  2. Previous history of bezoars.
  3. Prior GI surgery except for cholecystectomy, appendectomy, or Nissen fundoplication
  4. Any abdominal surgery within the past 3 months
  5. Known or history of inflammatory bowel disease
  6. History of diverticulitis, diverticular stricture, and other intestinal strictures
  7. Tobacco use within eight hours prior to capsule ingestion and during the initial 8 hour recording on Day 0 or the Ingestion visit.
  8. Alcohol use within eight hours prior to capsule ingestion and throughout the entire monitoring period (5 days).
  9. BMI > 40 kg/m2
  10. Allergies to components of the SmartBar (Appendix IX).
  11. Females of childbearing age who are not practicing birth control and/or are pregnant or lactating. (A urine pregnancy test will be performed on female subjects prior to capsule ingestion). Acceptable forms of birth control include oral contraceptives, double barrier method, and IUD cover and must be practiced from the time of enrollment until the time of release from the study.
  12. Cardiovascular, endocrine, renal, or other chronic disease likely to affect motility.
  13. Use of medical devices such as pacemakers, infusion pumps, or insulin pumps.
  14. Any contraindication to use of Fleets Enema.
  15. Uncontrolled diabetes with a hemoglobin A1C greater than 10%.
  16. Severe dysphagia to food or pills

    -

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
210 participants (estimated)

Groups and cohorts

  • Constipated

    Adult subjects with functional constipation as define by Rome II criteria

06

What researchers measure

Primary outcomes

  1. Colonic Transit Time

    Time frame: 4 days and 7 days

Secondary outcomes

  1. Determine regional gut (gastric, small bowel, colonic) transit times

    Time frame: continuous time measure until caspule elimination

07

Study locations

1 of 13 sites recruiting
  • University of Arizona Health and Sciences Ctr Southern Arizona VA HealthCare System
    Tucson, Arizona 85723, United States
    Withdrawn
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
    Completed
  • University of Iowa
    Iowa City, Iowa 52242, United States
    Completed
  • University of Kansas Med Center
    Kansas City, Kansas 66160, United States
    Completed
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Completed
  • University of Michigan Med Center
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Jasper Clinic, Inc.
    Kalamazoo, Michigan 49007, United States
    Completed
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Completed
  • University of Buffalo VA Medical Center
    Buffalo, New York 14215, United States
    Completed
  • University of North Carolina Medical Center
    Chapel Hill, North Carolina 27516, United States
    Completed
  • Wake Forest University Medical Center
    Winston Salem, North Carolina 27157, United States
    Completed
  • Temple University Medical Center
    Philadelphia, Pennsylvania 19140, United States
    Completed
  • Queen Mary, University of London
    London, United Kingdom
    Completed
08

References and documents

Publications

  • Camilleri M, Thorne NK, Ringel Y, Hasler WL, Kuo B, Esfandyari T, Gupta A, Scott SM, McCallum RW, Parkman HP, Soffer E, Wilding GE, Semler JR, Rao SS. Wireless pH-motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. Neurogastroenterol Motil. 2010 Aug;22(8):874-82, e233. doi: 10.1111/j.1365-2982.2010.01517.x. Epub 2010 May 11. PubMed 20465593 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 15, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00857363
Lead sponsor
The SmartPill Corporation
First posted
Mar 6, 2009
Start date
Mar 2009
Primary completion
May 2009 (estimated)
Completion
Jun 2009 (estimated)
Last update
Jan 15, 2010

Study contacts

Kelli Regan
Contact
kregan@smartpillcorp.com
716-882-0701 ext. 120
Tracy Crawford
Contact
tcrawford@smartpillcorp.com
716-882-0701 ext. 124
John R Semler, PHD
study chair · The SmartPill Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion